China’s Shenzhen Geno-Immune Medical Institute has embarked on a vaccine (LV-SMENP) clinical trial centering on a genetically modified vaccine to target the SARS-CoV-2 spike protein. The Context Back in December 2019 during the original pandemic breakout in Wuhan,...